Biomed Lublin S.A. develops Polish drug for Covid-19

The biotechnology company Biomed Lublin S.A. announced that it has successfully completed the first stage of production of the Polish drug for Covid-19. It was created as a result of fractionation of the plasma of convalescents or those who had passed the coronavirus asymptomatically. The drug will go to clinical trials – the company announced during a press conference held at the Medical University of Lublin.

The company from Lublin declares that if everything goes according to plan, Poland will be the first country in the world in a few months to have an effective drug “neutralizing the virus”.

Based on the technology of human plasma fractionation owned by Biomed Lublin, the company has produced an active substance that has been tested for the activity and effectiveness of fighting the SARS-CoV-2 virus by the team of Professor Krzysztof Pyrcia from the Małopolska Center of Biotechnology of the Jagiellonian University, cooperating on the project with the Institute of Hematology and Transfusion Medicine – said Piotr Fic, member of the management board of the Lublin company.

More than three thousand ampoules of anti-SARS-CoV-2 immunoglobulin were produced. They will be submitted for clinical use in Lublin, Bytom, Białystok and Warsaw after the completion of the required qualitative tests.

One Biomed share, in the afternoon of Wednesday, September 23, cost about PLN 22 on the Warsaw Stock Exchange, and at the end of last week it was only PLN 12.